WAVERLEY PHARMA INC.WW

WAVERLEY PHARMA INC.

0.0065EURD
0.00000.00%
Last update at Jan 20, 05:54 GMT
EUR
No trades
See on Supercharts

5GZ fundamentals

Key facts

Market capitalization‪468.43 K‬EUR
Basic EPS (TTM)−0.03EUR
Founded2014
CEOLarry Thiessen
About

Waverley Pharma, Inc. is a pharmaceutical company, which engages in the commercialization and development of oncology drugs. Its products include Pemetrexed, WAV-102, and PARP-1 Inhibitors. The company was founded in 2014 and is headquartered in Winnipeg, Canada.

Ownership
‪‪54.00 M‬‬
Closely held shares
‪‪40.45 M‬‬ (74.9%)
Free Float shares
‪‪13.55 M‬‬ (25.1%)
Closely held shares
‪‪40.45 M‬‬ (74.9%)
Free Float shares
‪‪13.55 M‬‬ (25.1%)
Capital structure
Market cap
‪‪468.43 K‬‬
Debt
‪‪1.97 M‬‬
Cash & equivalents
‪‪158.84 K‬‬
Enterprise value
‪‪2.27 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪468.43 K‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
7.39x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
7.39x
Valuation ratios
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪4.00‬
‪8.00‬
‪12.00‬
‪16.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−3,100.0%‬
‪−2,400.0%‬
‪−1,700.0%‬
‪−1,000.0%‬
‪−300.0%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−1.05 M‬‬
‪‪−700.00 K‬‬
‪‪−350.00 K‬‬
‪0.00‬
‪‪350.00 K‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−210.00 K‬‬
‪‪−140.00 K‬‬
‪‪−70.00 K‬‬
‪0.00‬
‪‪70.00 K‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−210.00 K‬‬
‪‪−140.00 K‬‬
‪‪−70.00 K‬‬
‪0.00‬
‪‪70.00 K‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Biopharmaceutical
By country
Period: 2023
United Kingdom

Dividends

Dividend yield, history and sustainability

5GZ does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−700.00 K‬‬
‪0.00‬
‪‪700.00 K‬‬
‪‪1.40 M‬‬
‪‪2.10 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪600.00 K‬‬
‪‪1.20 M‬‬
‪‪1.80 M‬‬
‪‪2.40 M‬‬
Assets
Liabilities